. .

Themis Bioscience Postpones its Listing on Euronext Amsterdam

Vienna, Austria, November 8, 2018 – Themis Bioscience N.V. (“Themis” or the “Company”), a biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, announced today that it has decided to postpone its listing on Euronext Amsterdam due to adverse market conditions, concluding that an IPO would not be in the interest of the Company or its shareholders at this time. Themis will continue to investigate all strategic options, including financings, for the development of its programs.

About Themis

Themis is developing immunomodulation therapies for infectious diseases and cancer. Through advanced understanding of immune system mechanisms, the Company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches. Initially focused on preventing infectious diseases, the Company has demonstrated the potential of its versatile platform through the rapid progression into Phase 2 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Funded to date by leading Europe-based VCs, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications. The Company will apply its platform and commercial manufacturing capabilities to diseases with high market potential both alone and for its partners. For more information, visit http://www.themisbio.com.

Contact

For Themis:
Dr. Erich Tauber, CEO
Phone: +43 1 236 7151
erich.tauber@themisbio.com

Media & Investor Inquiries for Themis:
Gretchen Schweitzer or Dr. Stephanie May
Trophic Communications
Phone: +49 89 2388 7730 or +49 171 185 56 82
may@trophic.eu

 

News archive
    NO ACTIVE WIDGETS